Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 8982 results

  1. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 April 2026.

    Technology appraisal guidance
    In consultation

  3. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 11 May 2026.

    Technology appraisal guidance
    In consultation

  5. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 28 April 2026.

    Technology appraisal guidance
    In consultation

  6. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Awaiting development Reference number: GID-TA11956 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 1 May 2026.

    Technology appraisal guidance
    In consultation

  8. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date:  05 June 2026

    NICE guideline
    In development

  11. Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]

    Awaiting development Reference number: GID-TA11935 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

    NICE guideline
    In development

  13. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTE10090 Expected publication date:  10 March 2027

    Health technology evaluations
    In development

  14. Cervical ripening ballon for the induction of labour in women who have previously undergone cesarean section

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation